Purpose: The frequency of drug administration errors and incompatibilities between intravenous drugs before and after an intervention in an intensive care unit (ICU) is discussed. Methods: Critically ...
To ensure safety throughout the supply chain and in the patient’s home, providers are adopting tamper-evident products for intravenous home infusion. To better understand the steps home infusion ...
The following article was originally published in Preventing Infection in Ambulatory Care, the quarterly e-publication from the Association for Professionals in Infection Control and Epidemiology ...
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...
The U.S. Food and Drug Administration (FDA) have granted approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), ...
A new study has found that specific regions of the brain are activated after a drug is taken intravenously but not when the same drug is taken orally, with increased activity correlating to an ...
Zacks Investment Research on MSN
J&J wins FDA nod for subcutaneous version of NSCLC drug Rybrevant (revised)
Johnson & Johnson JNJ announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its EGFR/MET ...
Today, the U.S. Food and Drug Administration approved Nexviazyme (avalglucosidase alfa-ngpt) for intravenous infusion to treat patients 1 year of age and older with late-onset Pompe disease. Patients ...
Drug therapy is a complex process with numerous parameters modulating its success and safety. The selection of a drug and the definition of its dosage regimen, which must consider both disease and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback